BTK and primary central nervous system lymphoma: Most phase III clinical trials on BTK inhibitors in PCNSL are ongoing, and we expect that more evidence will be available to confirm the efficacy, safety, and resistance of BTK inhibitors in PCNSL, with the goal of providing a basis for individualized treatment of patients with PCNSL in the real world.